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Abstract 
Background: It is unclear whether cardiovascular risk factor modification influences the 
development of renal disease in people with type 2 diabetes identified through screening. We 
determined predictors of albuminuria five years after a diagnosis of screen-detected diabetes 
within the ADDITION-Europe study, a pragmatic cardiovascular outcome trial of 
multifactorial cardiovascular risk management.  
Methods: In 1,826 participants with newly diagnosed, screen-detected diabetes without 
albumiuria, we explored associations between risk of new albuminuria (≥2.5mg mmol-1 
males and ≥3.5mg mmol-1 females) and: 1) baseline cardio-metabolic risk factors and 2) 
changes from baseline to one year in systolic blood pressure (∆SBP) and glycated 
haemoglobin (∆HbA1c) using logistic regression. 
Results: Albuminuria developed in 268 (15%) participants; baseline body mass index and 
active smoking were independently associated with new onset albuminuria in the five years 
after detection of diabetes. In a model adjusted for age, gender, and baseline HbA1c and blood 
pressure, a 1% decrease in HbA1c and 5 mmHg decrease in SBP during the first year were 
independently associated with lower risks of albuminuria (Odds Ratio (OR), 95% confidence 
interval: 0.76, 0.62 to 0.91 and 0.94, 0.88 to 1.01, respectively). Further adjustment did not 
materially change these estimates. There was no interaction between ΔSBP and ΔHBA1c in 
relation to albuminuria risk, suggesting likely additive effects on renal microvascular disease. 
Conclusions: Baseline measurements and changes in HbA1c and SBP a year after diagnosis 
of diabetes through screening independently associate with new onset albuminuria four years 
later. Established multifactorial treatment for diabetes applies to cases identified through 
screening.  
 
Keywords: Screening, type 2 diabetes, systolic blood pressure, albuminuria, microvascular 
complications, ADDITION-Europe  
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Introduction 
People with type 2 diabetes are often simultaneously exposed to a number of cardiovascular 
disease risk factors in addition to hyperglycaemia, with likely cumulative effects on 
complications frequency [1,2]. Diabetes case finding through screening theoretically enables 
identification of risk factors earlier in the disease trajectory, presenting an opportunity for 
aggressive multifactorial intervention which is not possible until later following other 
methods of diagnosis [3]. Although a strategy combining optimised blood pressure, glucose 
and lipids plus anti-platelet therapy has been shown to reduce the frequency of complications 
in patients with longstanding diabetes and microalbuminuria [4], this has not been 
demonstrated in “screen-detected” type 2 diabetes [5,6]. Shorter duration of treatment 
exposure, coupled with a low initial risk of major complications limit attempts to quantify 
individual or cumulative effects of risk factor modification in this population. It is unknown 
whether long term effects of initial intensive blood pressure and blood glucose control seen in 
patients with established diabetes will be similar in screen-detected cases
 
[7,8]. 
Albuminuria is a biomarker of early chronic kidney disease which independently predicts 
adverse renal and cardiovascular outcomes in both type 2 diabetes and essential hypertension, 
although albuminuria does not necessarily indicate the presence of early kidney disease. 
[9,10]. Its management in hypertensive patients with type 2 diabetes has been shown to be 
particularly effective if initiated early [11].  
We aimed to quantify the association between baseline characteristics, treatment associated 
changes in risk factors in the year following diagnosis and development of albuminuria over 
five years in a cohort of people with screen detected type 2 diabetes. 
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Materials and Methods 
Addition Europe  
The study design and rationale of the randomised controlled trial of multifactorial 
cardiovascular risk modification has been described elsewhere [12]. Briefly, ADDITION-
Europe comprises a screening phase and a five year pragmatic, cluster randomized, parallel 
group intervention trial in four European centers (Denmark; the Netherlands; Cambridge, 
United Kingdom; and Leicester, United Kingdom). The study was approved by local ethics 
committees in each center. All participants provided informed consent. 379 general practices 
took part and were independently randomized to screening plus routine care for diabetes or 
screening followed by intensive treatment. Screening programs among people aged 40–69 
years, without known diabetes, included an oral glucose tolerance test for all individuals in 
Leicester and a stepwise screening program using random glucose measurements and 
glycated haemoglobin (HbA1c) followed by fasting glucose and oral glucose tolerance test in 
all other centers [13,14]. The diagnosis of diabetes was based on World Health Organization 
criteria. Intervention targets and algorithms for the intensive group were identical in all 
centers; HbA1c ≤7.0% (53 mmolmol
-1
), blood pressure ≤130/70mmHg and serum total 
cholesterol ≤3.5 mmoll-1 [12]. Although treatment targets were specified and classes of drugs 
recommended, the choice of therapy was made by prescribing clinicians and by patients. 
Therefore it is not possible to determine independent drug effects on albuminuria 
development. Routine care practices delivered diabetes care according to national guidelines. 
All participants, with the exception of those in Denmark for blood pressure, underwent an 
interim assessment after one year irrespective of treatment allocation. This included 
standardised measurements of height, weight, blood pressure and HbA1c. The results of 
intensive vs routine care treatment for the primary and secondary outcomes have been 
previously reported [5,6]. 
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Variables assessment and study outcomes 
Baseline and one year health assessments (completed December 2005) included biochemical, 
anthropometric, and questionnaire measures, and were undertaken by centrally trained staff 
following standard operating procedures unaware of study group allocation. Follow-up (five 
year) examinations took place from September 2008 to the end of December 2009. 
Biochemical measures were analysed in five regional laboratories at baseline and follow-up. 
Standardized self-report questionnaires were used to collect information on socio-
demographic characteristics (age, sex, and ethnicity), smoking status, and prescribed 
medication. Information on HbA1c and systolic blood pressure were also available in all 
centres (other than blood pressure in Denmark) one year after study randomization. 
Albuminuria (defined as albumin-to-creatinine ratio (ACR) ≥2.5 mg/mmol for males and 
≥3.5 mg/mmol for females on timed (morning) sampling [15]) at the end of follow-up was 
the main outcome for this study. At baseline and follow-up, morning spot urine ACR was 
measured with a Roche Hitachi 912 chemistry analyzer at Aarhus Hospital (Aarhus, 
Denmark) and the Steno Diabetes Centre (Gentofte, Denmark), an Olympus AU400 analyser 
at Addenbrooke’s Hospital (Cambridge, United Kingdom) and the Royal Infirmary 
(Leicester, United Kingdom), and a Roche/Hitachi Modular P analyzer at the SHL Centre for 
Diagnostic Support in Primary Care (Etten-Leur, Netherlands). Repeated analyses of 
standardized trial control samples for urine creatinine levels during follow-up confirmed 
reliability and precision of laboratory methods with coefficients of variation (CVs) <3.4% in 
all laboratories. Analyses of trial and external quality control samples of urine albumin 
revealed CVs between 2.0% and 9.8% in Etten-Leur, Leicester, and Gentofte and 4.9% and 
3.4% for low and high concentrations, respectively, in Cambridge during the trial testing 
period.  
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Statistical analysis 
Complete case analyses aimed to explore; 1) independent baseline predictors of 5-year 
albuminuria in people with diabetes identified by screening and 2) associations between 
changes in systolic blood pressure and HbA1c from baseline to one year after randomization 
(∆SBP and ∆HbA1c, respectively) and subsequent 5-year risk of albuminuria. Association 
were estimated per 5mmHg and 1% (10.9 mmol/mol) reduction of SBP and HbA1c, 
respectively, as these were felt to be readily attainable changes commonly seen in clinical 
practice following a diagnosis of type 2 diabetes.  
Participant demographic and clinical characteristics were summarized using means and 
standard deviation (SD) or frequencies and percentages, as appropriate. Multivariable logistic 
regression analyses were performed to assess associations between baseline HbA1c, SBP, 
body mass index and cholesterol measurements and the likelihood of a microvascular renal 
outcome (presence of albuminuria). This allowed gender specific definitions of albuminuria 
to be incorporated into a combined logistic analysis. Associations between ∆HbA1c and ∆SBP 
at one year with risk of albuminuria at the end of follow-up were estimated in logistic 
regression analyses adjusted for age, gender, baseline HbA1c and baseline SBP (model 1); 
further adjustment included baseline smoking status (model 2), total cholesterol (model 3), 
and body mass index (model 4). Following a two-step approach, odds ratios (ORs) were 
firstly estimated for each centre and then pooled with a fixed-effect meta-analysis according 
to trial protocol analysis. Centre-specific and overall ORs were displayed using forest plots, 
and the proportion of variability between centers due to heterogeneity was computed as I
2
. 
Two-sided statistical tests were performed with Stata 14 (Stata Corp, College Station, TX, 
USA), and results are reported with 95% confidence intervals. 
 
Results  
Study Population 
A total of 3,057 patients were identified with screen-detected type 2 diabetes from four 
participating centres and entered the trial phase of the study. Participants with prevalent 
albuminuria at baseline (n=547), or with missing data at baseline (n=312) or follow-up 
(n=372), were excluded, leaving a total of 1,826 for this observational cohort analysis. 
 This article is protected by copyright. All rights reserved. 
Baseline and follow up characteristics 
At baseline, mean (SD) age was 59.9 (6.9) years old, systolic blood pressure 147 (20) mmHg, 
HbA1c 6.9% (1.4) [52 mmol mol
-1
 (16)], and eGFR 75.0 (16.1) mL/min/1.73m
2
. 57% were 
males and 25% were current smokers (Table 1). After a mean (SD) follow-up of 5.3 (1.6) 
years, eGFR was 80.8 (19.5) mL/min/1.73m
2
 and 268 (15%) cases of albuminuria were 
recorded. At one year follow-up, mean HbA1c values were 0.6% (6.5 mmol mol
-1
) and 0.5% 
(6.0 mmol mol
-1
) lower in the subsequently determined cases and non-cases of albuminuria, 
respectively. Similarly, systolic blood pressure was 11 (24) mmHg lower in cases and 12 (21) 
mmHg lower in non-cases (Table 1).  
In a multivariable analysis, baseline age, active smoking and body mass index were 
positively associated with albuminuria. Male gender but not baseline total plasma cholesterol, 
HbA1c or SBP was also associated with development of albuminuria (Table 2).   
 
Change in HbA1c and systolic blood pressure between baseline and one year follow up and 
albuminuria risk 
In analyses adjusted for age, gender, baseline HbA1c, and baseline blood pressure (1597 
participants, 236 incident cases) a one unit (1% or 10.9 mmol/mol) decrease in ∆HbA1c was 
associated with a 24% lower risk of albuminuria at five years (OR 0.76, 0.62 to 0.91). This 
association persisted after additional adjustment for smoking (model 2), total cholesterol 
(model 3) and body mass index (model 4) (Fig. 1). Moderate heterogeneity was found across 
centres for all the models. The inclusion of baseline ACR to model 4 did not change the 
estimate (OR 0.79; 0.64 to 0.98). 
In analyses adjusted for age, gender, baseline HbA1c, and baseline blood pressure (764 
participants, 93 incident cases), a 5 mmHg decrease in ∆SBP was associated with a 6% lower 
risk of albuminuria at five years (Odds Ratio (OR), 95% confidence interval: 0.94, 0.88 to 
1.00), corresponding to 1% and 12% risk reduction in five year albuminuria with a 1mmHg 
and 10 mmHg ΔSBP, respectively assuming a linear relationship. The association was similar 
after adjustment for smoking, total cholesterol and body mass index (Figure 1) and adding 
baseline ACR to model 4 (OR 0.93; 0.87 to 0.99). Moderate heterogeneity was found across 
centres for all the models. 
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Sensitivity analyses demonstrated no statistically significant interaction between ΔHBA1c and 
ΔSBP and risk of albuminuria in any model (eg. p for interaction ≥0.545).   
 
Discussion  
Previous studies have shown that the risk of microvascular complications is significantly 
reduced by intensive blood glucose or blood pressure control in individuals with established 
type 2 diabetes, with no obvious threshold across blood pressure or glycated haemoglobin 
ranges [16-20]. As microvascular disease is linked to duration and initial control of 
hyperglycaemia, it follows that aggressively intervening earlier in the disease may be 
advantageous [21]. Albuminuria is an important independent risk factor for cardiovascular 
mortality in diabetes and its management has been shown to reduce the risk of progressive 
renal disease [22,23]. 
We have demonstrated that with the exception of dyslipidaemia, reversible determinants of 
incipient reno-vascular disease appear similar for patients detected by screening and therefore 
at an earlier stage of type 2 diabetes. A 1% reduction in HbA1c was associated with a 
significant 24% lower risk of albuminuria five years after diagnosis. A 5 mmHg change in 
blood pressure within the first year of diagnosis was also associated with a lower risk of this 
clinically important outcome. This risk reduction is similar to other modelled findings 
exploring microvascular disease outcomes in patients with type 2 diabetes and the estimated 
one year cardiovascular risk factor modification is within that expected of current clinical 
practice.   
Whilst we found no association with plasma total cholesterol concentration, previous studies 
have linked hypertriglyceridemia with diabetes-related renal disease, although these did not 
adjust for baseline body mass index [24,25]. Epidemiological studies consistently 
demonstrate that in the general population, individuals who are overweight (BMI 25-29 
kg/m
2
) or obese have an increased risk of chronic kidney disease [26], and this also appears 
to be the case in this population with early onset diabetes, independent of glucose 
concentration. The importance of fat mass and its pro-inflammatory and or metabolic 
sequelae in the pathogenesis of renal disease warrants further investigation.  
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Our interaction analyses did not demonstrate any relationship between changes in blood 
pressure and glucose and 5-year albuminuria risk. Combined intensive blood pressure 
lowering and glucose control in the ADVANCE (Action in Diabetes and Vascular Disease: 
Preterax and Diamicron MR Controlled Evaluation) trial reduced the risk of new onset 
microalbuminuria by approximately 25% after 4.3 years of follow up [18,19]. The 2x2 
factorial design of ADVANCE allowed independent assessment of risk factor management 
on outcomes and concluded that blood pressure and blood glucose lowering result in separate, 
additive effects on renal microvascular disease [27]. Whilst the multifactorial intervention of 
ADDITION Europe limits the ability to draw firm conclusions in respect to individual 
treatment strategies, the magnitude of reduction in albuminuria risk associated with blood 
pressure and blood glucose lowering appears consistent across the studies, and suggests likely 
benefits from this approach in cases identified through screening.  
Observed lack of risk factor interplay in these analyses suggest that either independent (and 
independently treatable) vasculopathic mechanisms contribute to renal complications in type 
2 diabetes irrespective of disease duration or that sample sizes are insufficient to detect 
statistically meaningful interactions. Although we are unable to definitively exclude any 
interaction without a much larger and longer study, we are confident that this result supports 
the current multifactorial treatment paradigm for type 2 diabetes. 
The findings of this analysis need to be placed in context with those of the ADDITION-
Europe randomised controlled trial [5]. This study concluded that compared to routine care, 
five years of target driven intensive multifactorial management of patients with type 2 
diabetes detected by screening is not associated with significant reductions in the frequency 
of microvascular events, including microalbuminuria. An explanation for this observation 
relates to smaller-than-expected differences between the treatment groups, rather than lack of 
efficacy of the chosen multifactorial treatment approach in screen-detected cases. In fact both 
intensive and routine care arms of the trial saw reductions in the number of cases of 
microalbuminuria. Simulation models consistently indicate major benefits are likely to accrue 
from the early diagnosis and treatment of hyperglycaemia and other cardiovascular risk 
factors in people with type 2 diabetes [3,28].    
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There are some limitations of this study in addition to the reliance on associative analyses 
already alluded to. Firstly, an experimental design controlling for individual risk factor 
exposure may allow stronger causal conclusions to be drawn and it may be important to 
consider additional lipid indices and/or anthropometrics when constructing models relevant to 
renal outcomes. Secondly, we opted to perform complete case analyses and did not impute 
missing data, acknowledging that the lack of availability of one year data in one centre 
reduced the sample population. Although the number of new cases of albuminuria was 
sufficient to allow meaningful comparisons, independent effects of particular treatments or 
drug classes were not possible due to the pragmatic nature of the ADDITION-Europe 
intervention. We felt albuminuria development in people with diabetes is a clinically 
significant event worthy of reporting but acknowledge its transitory nature in clinical 
practice. We did not take into account the possibility of subsequent regression to 
normoalbuminuria in some cases or the likely importance of other markers of renal disease 
(eg. eGFR decline). Whilst linking to more patient identifiable outcomes such as end-stage 
renal or cardiac disease is of relevance, this would require a much longer follow up period 
and larger sample size. The impact of microvascular disease burden on the development of 
albuminuria eg. presence of retinopathy and neuropathy, could not be ascertained as these 
were not quantified at baseline. Despite these caveats we feel that this study improves our 
understanding of early onset type 2 diabetes, and more importantly the likely effectiveness of 
widely adopted complication prevention strategies. To our knowledge this is the largest 
cohort of screened cases of type 2 diabetes, with well defined, repeated measurements 
allowing statistical approaches which can infer independent associations with clinically 
important outcomes. 
In conclusion, active smoking and body mass index are independently associated with the 
development of albuminuria in patients with type 2 diabetes identified through screening. 
Subsequent improvement in blood pressure control a year after diagnosis in these patients is 
independently associated with lower risk of new onset albuminuria four years later.   
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Table 1. Baseline and one year characteristics of the ADDITION-Europe population included in the study (N=1826) according to 
presence of albuminuria (cases) at 5-year follow up 
 
Data are reported as n (%) for the categorical variables Gender and Smoking 
HbA1c: Glycated Haemoglobin; SBP: Systolic Blood Pressure; SD: Standard deviation 
∆ = 1 year value – baseline value 
# Estimated using the MDRD (Modification of Diet in Renal Disease) formula; values normalised to 1.73 m
2 
 
* 21 missing data (18 noncases and 3 cases) 
 
 
 
 
 
BASELINE 
 
 1-YEAR CHANGES 
 
1-YEAR CHANGES 
 
 
Age 
(Years) 
SBP 
(mmHg) 
Cholesterol 
(mmol/L) 
HbA1c 
(%)/ 
(mmol/mol) 
BMI 
(Kg/m
2
) 
eGFR  
(mL/min)* 
Gender 
(Males) 
Smoking
#
 
(Yes) 
 HbA1c  
(%)/ 
(mmol/mol) 
SBP 
(mmHg)  
∆HbA1c  
(%)/ 
(mmol/mol) 
∆SBP 
(mmHg) 
Albuminuria 
Cases (N=268) 
     
 
  
 
 
     Mean / n (%) 
 
61.0 149 5.6 7.1/54 31.7 73.8 168 (62.7) 95 (35.8)  6.5/48 138 
 
-0.6/-6.5 -11 
SD 
 
6.9 20 1.1 1.6/17 5.5 16.2 - -  0.9/10 19 
 
  1.4/15.0   24 
Non cases 
(N=1558) 
 
    
   
 
 
     
Mean / n (%) 
 
59.7 146 5.6 6.9/52 31.4 75.2 874 (56.1) 347 (22.5)  6.4/46 134 
 
-0.5/-6.0 -12 
SD 
 
6.8 20 3.8 1.4/15 5.4 16.0 - -  0.7/8 18 
 
   1.3/14.0   21 
Total  
(N=1826) 
 
    
   
 
 
     
Mean / n (%) 
 
59.9 147 5.6 6.9/52 31.5 75.0 1042 (57.1) 442 (24.5)  6.4/46 135 
 
-0.5/-6.1 -11 
SD 
 
6.9 20 3.6 1.4/16 5.4 16.1 - -  0.8/8.4 18 
 
   1.3/14.1   22 
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Table 2: Multivariable associations of baseline risk factors with the presence of 
albuminuria at 5-year follow-up 
    95% CI   
Risk factor 
 
OR 
 
Lower Upper 
 
p-value 
Age (years) 
 
1.044  1.021 1.068  <0.001 
Gender (M) 
 
1.456  1.079 1.963  0.014 
Systolic Blood Pressure (mmHg) 
 
1.003  0.996 1.010  0.425 
HbA1c (%) 
 
1.097  0.998 1.207  0.054 
Smoking (Active) 
 
1.864  1.367 2.542  <0.001 
Total Cholesterol (mmol/L) 
 
1.072  0.941 1.220  0.297 
Body Mass Index (kg/m
2
) 
 
1.045  1.017 1.074  0.001 
 
Odds Ratios (OR) per unit increase of risk factors were estimated for each centre and then combined in a 
multivariate fixed-effect meta-analysis.   
1% change HbA1c = 10.9 mmol/mol 
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Figure 1: Association between changes in HBA1c and systolic blood pressure and the presence of 
5-year albuminuria 
Legend 
Data are combined in fixed-effect meta-analyses DK=Denmark; UK=United Kingdom; 
NL=Netherlands Adjustments: Model 1:  Age, gender, HbA1c, systolic blood pressure; Model 2: 
Model 1 + smoking; Model 3: Model 2+ total cholesterol; Model 4: Model 3 + body mass index 
1% change HbA1c = 10.9 mmol/mol 
 
 
